Current guidelines consider diabetes per se as a coronary artery disease (CAD) risk equivalent. We aimed at investigating the contribution of baseline coronary atherosclerosis to the risk of diabetic patients for future vascular events. Design Prospective cohort study.
Methods
Vascular events were recorded over 4 years in 750 consecutive patients undergoing coronary angiography for the evaluation of stable CAD.
Results
From our patients, 244 had neither type 2 diabetes (T2DM) nor significant CAD (i.e. coronary stenoses ≥ 50%) at the baseline angiography, 50 had T2DM but not significant CAD, 342 did not have T2DM but had significant CAD, and 114 had both T2DM and significant CAD. Nondiabetic patients without significant CAD had an event rate of 9.0%. The event rate was similar in T2DM patients without significant CAD (8.0%, P = 0.951), but higher in nondiabetic patients with significant CAD (24.9%, P < 0.001). Patients with T2DM and significant CAD had the highest event rate (43.0%). Importantly, T2DM patients without significant CAD had a significantly lower event rate than nondiabetic patients with significant CAD (P = 0.008).
Conclusion
T2DM per se is not a CAD risk equivalent. Moderate-risk diabetic patients without significant CAD and very high-risk diabetic patients with significant CAD add up to a grand total of high-risk diabetic patients, this is why diabetes seems to be a CAD risk equivalent in many epidemiological studies.
HaffnerSMLehtoSRonnemaaTPyoralaKLaaksoM.Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med1998; 339:229–234.
2.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA2001; 285:2486–2497.
3.
WhiteleyLPadmanabhanSHoleDIslesC.Should diabetes be considered a coronary heart disease risk equivalent? results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care2005; 28:1588–1593.
4.
MalmbergKYusufSGersteinHCBrownJZhaoFHuntD, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation2000; 102:1014–1019.
5.
MukamalKJNestoRWCohenMCMullerJEMaclureMSherwoodJB, et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care2001; 24:1422–1427.
6.
NatarajanSLiaoYSinhaDCaoGMcGeeDLLipsitzSR.Sex differences in the effect of diabetes duration on coronary heart disease mortality. Arch Intern Med2005; 165:430–435.
7.
JuutilainenALehtoSRonnemaaTPyoralaKLaaksoM.Type 2 diabetes as a coronary heart disease equivalent: an 18-year prospective population-based study in Finnish subjects. Diabetes Care2005; 28:2901–2907.
8.
SimonsLASimonsJ.Diabetes and coronary heart disease. N Engl J Med1998; 339:1714–1715.
9.
LotufoPAGazianoJMChaeCUAjaniUAMoreno-JohnGBuringJE, et al. Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med2001; 161:242–247.
10.
EvansJMWangJMorrisAD.Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ2002; 324:939–942.
11.
LeeCDFolsomARPankowJSBrancatiFL.Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation2004; 109:855–860.
12.
VaccaroOEberlyLENeatonJDYangLRiccardiGStamlerJ.Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the multiple risk factor intervention trial. Arch Intern Med2004; 164:1438–1443.
13.
ChoERimmEBStampferMJWillettWCHuFB.The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol2002; 40:954–960.
14.
BeckerABosGde VegtFKostensePJDekkerJMNijpelsG, et al. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study. Eur Heart J2003; 24:1406–1413.
15.
HuGJousilahtiPQiaoQPeltonenMKatohSTuomilehtoJ.The gender-specific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease. J Am Coll Cardiol2005; 45:1413–1418.
16.
BuykenAEvon EckardsteinASchulteHCullenPAssmannG.Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study. Eur J Cardiovasc Prev Rehabil2007; 14:230–236.
17.
DrexelHAczelSMarteTBenzerWLangerPMollWDrexelH.Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care2005; 28:101–107.
18.
DrexelHAmannFWBeranJRentschKCandinasRMuntwylerJ, et al. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation1994; 90:2230–2235.
19.
BulugahapitiyaUSiyambalapitiyaSSitholeJIdrisI.Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med2009; 26:142–148.
20.
HuFBStampferMJSolomonCGLiuSWillettWCSpeizerFE, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med2001; 161:1717–1723.
21.
BuseJBGinsbergHNBakrisGLClarkNGCostaFEckelR, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation2007; 115:114–126.
22.
OgawaHNakayamaMMorimotoTUemuraSKanauchiMDoiN, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA2008; 300:2134–2141.
23.
SaelyCHAczelSMarteTLangerPDrexelH.Cardiovascular complications in Type 2 diabetes mellitus depend on the coronary angiographic state rather than on the diabetic state. Diabetologia2004; 47:145–146.
24.
AnselminoMMalmbergKOhrvikJRydenL.Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur J Cardiovasc Prev Rehabil2008; 15:216–223.
25.
KotsevaKWoodDDe BackerGDe BacquerDPyoralaKKeilU.EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil2009; 16:121–137.
26.
Jacobs-van der BruggenMAEngelfrietPMHoogenveenRTvan BaalPHStruijsJNVerschurenWM, et al. Lipid-lowering treatment for all could substantially reduce the burden of macrovascular complications of diabetes patients in the Netherlands. Eur J Cardiovasc Prev Rehabil2008; 15:521–525.
27.
LangerCWiemerMPeterschroderAFranzkeKMellwigKPvan BuurenF, et al. Stratification for noninvasive coronary angiography: patient preselection considering atypical angina pectoris, conventional cardiovascular risk assessment, and calcium scoring. Eur J Cardiovasc Prev Rehabil2009; 16:201–209.
